A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Active not recruiting 338 enrolled Hoffmann-La Roche Chugai Pharmaceutical · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).

Timeline

Start: 2024-09-23
Primary completion: 2026-05-19
Completion: 2029-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Adagrasib	Small molecule	—	Oral
Subject	Divarasib	Small molecule	—	Oral
Comparator	Sotorasib	Small molecule	—	Oral

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Summary

Timeline

Drugs

Indications